NASTECH PHARMACEUTICAL IS LOSING GROUND ON FDA

A A

Nastech Pharmaceutical announced Thursday morning that it received written notification from the FDA, on July 10, that the company's abbreviated new drug application for intranasal calcitonin-salmon is not approvable at this time. Trading Markets (http://www.tradingmarkets.com/tm.site/news/STOCK%20ALERT/304352/)